日本人健康男性被験者を対象に、静脈注射で投与されたBAY 1747846の安全性および体内濃度を単回投与量増加条件下でより詳細に調べるための研究

基本情報

NCT ID

NCT06125366

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

25

治験依頼者名

Bayer

概要

The goal of this clinical study was to learn more about BAY1747846 compared to placebo when given as an injection into the vein in Japanese healthy male participants: * the safety of BAY1747846 when given at increasing single doses * the level of BAY1747846 in the body over time when given at increasing single doses. To answer the first question, the researchers compared the number and severity of medical problems the Japanese participants had after receiving BAY 1747846 at increasing doses and placebo respectively. Doctors keep track of all medical problems that happen in studies, even if they do not think they might be related to the study treatments. To answer the second question, the researchers determined: * the (average) total level of BAY1747846 in the body, also called AUC * the (average) highest level of BAY1747846 in the body, also called Cmax * how BAY1747846 is removed from the body, also called clearance (CL).

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)